Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,498

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
10/03/26	90.49 $	-0.78%	1,373,083
09/03/26	91.20 $	0.00%	1,712,244
06/03/26	91.20 $	-1.49%	1,272,484
05/03/26	92.58 $	-0.47%	1,538,279
04/03/26	93.02 $	-0.30%	1,070,795

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

91.20USD

Average target price

132.57USD

Spread / Average Target

+45.36%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
90.49 ^USD	-0.78%		-1.89%	-11.41%

02:15pm	Guardant Health Inc Announces Shield Blood-Based Screening Test for Colorectal Cancer Is Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	CI
03-05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT

Capitalization	11.96B 10.27B 9.29B 8.89B 16.24B 1,099B 16.75B 109B 43.79B 527B 44.9B 43.94B 1,886B	P/E ratio 2026 *	-30.7x	P/E ratio 2027 *	-42.8x
Enterprise value	12.37B 10.63B 9.6B 9.2B 16.8B 1,137B 17.33B 113B 45.3B 545B 46.44B 45.45B 1,951B	EV / Sales 2026 *	9.73x	EV / Sales 2027 *	7.62x
Free-Float	95.44%	Yield 2026 *	-	Yield 2027 *	-

02:15pm	Guardant Health Inc Announces Shield Blood-Based Screening Test for Colorectal Cancer Is Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	CI
03-05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
02-19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026
02-19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
02-19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Reports Q4 Revenue $281.3M, vs. FactSet Est of $272.4M	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Posts Q4 Adjusted Loss $0.50 per Share, vs. FactSet Est of $-0.77	MT
02-19	Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-19	Guardant Health, Inc. Provides Revenue Guidance for the Fiscal Year 2026	CI
02-18	Guardant Health, Inc. (NasdaqGS:GH) acquired Metasight Diagnostics for approximately $150 million.	CI
02-17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI

02-17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
12-02	Morgan Stanley Raises Price Target on Guardant Health to $130 From $105, Keeps Overweight Rating	MT
30/10/25	UBS Adjusts Guardant Health Price Target to $110 From $80, Maintains Buy Rating	MT
29/09/25	Guardant Health Says US FDA Approves its Blood Test as Companion Diagnostic for Eli Lilly's Inluriyo	MT

Guardant Health, Inc. Share Price

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Valuation: Guardant Health, Inc.

Chart: Guardant Health, Inc.

Latest news: Guardant Health, Inc.

Last Transcript: Guardant Health, Inc.

Analysts' recommendations: Guardant Health, Inc.

Press Releases: Guardant Health, Inc.

News in other languages: Guardant Health, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Guardant Health, Inc.

ETFs: Guardant Health, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12:06pm	Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	BU
03-04	Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America	BU
03-03	Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened	BU
02-27	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
02-19	Guardant Health: Q4 Earnings Snapshot	AQ

12-11	Guardant Health et le Policlinico Gemelli lancent un service interne de tests de biopsie liquide en Italie
12-11	Guardant Health und Policlinico Gemelli starten internen Flüssigbiopsie-Testdienst in Italien
17/10/25	Guardant Health et ses collaborateurs présenteront de nouvelles données sur le continuum des soins contre le cancer lors du congrès ESMO 2025
16/10/25	Guardant Health und Kooperationspartner präsentieren auf der ESMO 2025 neue Daten zur gesamten Krebsbehandlungskette
31/07/25	Guardant Health und James Van Der Beek schließen sich zusammen, um das Bewusstsein für neue Fortschritte bei der Darmkrebsvorsorge für Erwachsene ab 45 Jahren zu schärfen

1 day	-0.78%
1 week	-1.89%
Current month	-3.63%
1 month	-14.10%
3 months	-12.32%
6 months	+52.24%
Current year	-11.41%

1 week	88.29	96.52
1 month	88.21	113.78
Current year	88.21	120.74
1 year	36.36	120.74
3 years	15.81	120.74
5 years	15.81	169.42
10 years	15.81	181.07

Manager	Title	Age	Since
AmirAli Talasaz CEO	Chief Executive Officer	46	04/08/2021
Helmy Eltoukhy CEO	Chief Executive Officer	47	31/12/2012
Michael Bell DFI	Director of Finance/CFO	57	04/01/2021

Director	Title	Age	Since
Helmy Eltoukhy CHM	Chairman	47	04/08/2021
AmirAli Talasaz CHM	Chairman	46	31/12/2012
Ian Clark BRD	Director/Board Member	64	30/11/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GUARDANT HEALTH, INC.	-0.78%	-1.89%	+130.14%	+235.89%	11.96B
BIOMÉRIEUX	-0.37%	-5.89%	-17.56%	-1.95%	13.06B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+1.42%	+7.12%	-10.44%	-6.31%	6.07B
CARIS LIFE SCIENCES, INC.	-2.42%	-10.26%	-	-	5.37B
LANTHEUS HOLDINGS, INC.	+4.01%	+9.07%	-21.74%	+13.74%	5.17B
DIASORIN S.P.A.	+1.07%	-1.94%	-27.84%	-37.62%	4.3B
ANDON HEALTH CO., LTD.	+5.74%	+8.95%	+26.22%	+10.19%	3.06B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.95%	-1.45%	-15.95%	-42.74%	2.89B
10X GENOMICS, INC.	-2.15%	-11.58%	+74.87%	-56.52%	2.67B
VCANBIO CELL & GENE ENGINEERING CORP., LTD	+1.88%	+13.74%	+37.89%	+74.67%	2.03B
Average	+0.93%	+0.02%	+19.51%	+21.04%	5.66B
Weighted average by Cap.	+0.45%	-1.34%	+26.22%	+50.29%

	2026 *	2027 *
Net sales	1.27B 1.09B 987M 945M 1.73B 117B 1.78B 11.63B 4.66B 56.01B 4.77B 4.67B 201B	1.64B 1.4B 1.27B 1.22B 2.22B 150B 2.29B 14.96B 5.99B 72.03B 6.14B 6.01B 258B
Net income	-380M -326M -295M -282M -516M -34.89B -532M -3.47B -1.39B -16.73B -1.43B -1.4B -59.89B	-266M -229M -207M -198M -361M -24.44B -373M -2.43B -974M -11.72B -999M -978M -41.96B
Net Debt	411M 353M 319M 305M 558M 37.75B 576M 3.76B 1.5B 18.1B 1.54B 1.51B 64.81B	509M 437M 395M 378M 691M 46.77B 713M 4.66B 1.86B 22.42B 1.91B 1.87B 80.29B